American Century Companies Inc. Reduces Holdings in Moderna, Inc. (NASDAQ:MRNA)

American Century Companies Inc. trimmed its stake in Moderna, Inc. (NASDAQ:MRNA) by 1.3% in the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 78,963 shares of the company’s stock after selling 1,000 shares during the period. American Century Companies Inc.’s holdings in Moderna were worth $9,377,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also recently modified their holdings of the stock. Cedar Wealth Management LLC lifted its position in shares of Moderna by 45.0% in the 1st quarter. Cedar Wealth Management LLC now owns 290 shares of the company’s stock worth $31,000 after purchasing an additional 90 shares during the period. Commerzbank Aktiengesellschaft FI lifted its position in Moderna by 1.7% during the 2nd quarter. Commerzbank Aktiengesellschaft FI now owns 5,550 shares of the company’s stock valued at $660,000 after acquiring an additional 93 shares during the period. CVA Family Office LLC lifted its position in Moderna by 21.6% during the 2nd quarter. CVA Family Office LLC now owns 541 shares of the company’s stock valued at $64,000 after acquiring an additional 96 shares during the period. Claro Advisors LLC lifted its position in Moderna by 2.0% during the 2nd quarter. Claro Advisors LLC now owns 5,546 shares of the company’s stock valued at $659,000 after acquiring an additional 108 shares during the period. Finally, EverSource Wealth Advisors LLC lifted its position in Moderna by 32.3% during the 4th quarter. EverSource Wealth Advisors LLC now owns 475 shares of the company’s stock valued at $47,000 after acquiring an additional 116 shares during the period. 75.33% of the stock is owned by hedge funds and other institutional investors.

Insider Activity

In other news, President Stephen Hoge sold 15,000 shares of the business’s stock in a transaction that occurred on Monday, July 15th. The shares were sold at an average price of $121.12, for a total transaction of $1,816,800.00. Following the completion of the transaction, the president now directly owns 1,442,089 shares of the company’s stock, valued at $174,665,819.68. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. In other Moderna news, President Stephen Hoge sold 15,000 shares of the company’s stock in a transaction that occurred on Monday, July 15th. The shares were sold at an average price of $121.12, for a total transaction of $1,816,800.00. Following the completion of the sale, the president now directly owns 1,442,089 shares of the company’s stock, valued at $174,665,819.68. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Also, CFO James M. Mock sold 689 shares of the company’s stock in a transaction that occurred on Monday, July 8th. The shares were sold at an average price of $118.24, for a total transaction of $81,467.36. Following the sale, the chief financial officer now directly owns 7,269 shares of the company’s stock, valued at $859,486.56. The disclosure for this sale can be found here. Insiders sold 93,158 shares of company stock valued at $11,167,312 over the last three months. Insiders own 15.70% of the company’s stock.

Analyst Upgrades and Downgrades

MRNA has been the subject of a number of recent research reports. Deutsche Bank Aktiengesellschaft raised shares of Moderna from a “sell” rating to a “hold” rating and lowered their price target for the company from $85.00 to $80.00 in a research report on Wednesday, August 7th. Needham & Company LLC reissued a “hold” rating on shares of Moderna in a research report on Friday, September 13th. Barclays lowered their price target on shares of Moderna from $155.00 to $125.00 and set an “overweight” rating for the company in a research report on Monday, September 16th. Royal Bank of Canada reaffirmed a “sector perform” rating and issued a $75.00 target price on shares of Moderna in a report on Thursday. Finally, Oppenheimer cut shares of Moderna from an “outperform” rating to a “market perform” rating in a report on Friday, September 13th. Two analysts have rated the stock with a sell rating, thirteen have issued a hold rating and four have given a buy rating to the company’s stock. According to data from MarketBeat.com, the stock presently has an average rating of “Hold” and a consensus price target of $100.44.

Moderna Stock Down 3.4 %

MRNA opened at $65.69 on Monday. The company has a quick ratio of 3.92, a current ratio of 4.09 and a debt-to-equity ratio of 0.05. The firm has a 50 day moving average price of $90.07 and a 200-day moving average price of $110.96. Moderna, Inc. has a twelve month low of $62.55 and a twelve month high of $170.47. The stock has a market capitalization of $25.18 billion, a price-to-earnings ratio of -4.19 and a beta of 1.67.

Moderna (NASDAQ:MRNA) last released its quarterly earnings data on Thursday, August 1st. The company reported ($3.33) earnings per share for the quarter, beating the consensus estimate of ($3.47) by $0.14. Moderna had a negative net margin of 116.18% and a negative return on equity of 21.35%. The firm had revenue of $241.00 million during the quarter, compared to analysts’ expectations of $128.41 million. During the same period in the previous year, the company earned ($3.62) earnings per share. The firm’s quarterly revenue was down 29.9% on a year-over-year basis. Equities research analysts forecast that Moderna, Inc. will post -9.52 earnings per share for the current year.

Moderna Profile

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.